Full-Time

Finance Senior

Updated on 7/11/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Sant Cugat del Vallès, Barcelona, Spain

In Person

On-site in Barcelona, Spain.

Category
Accounting (2)
,

People at Cencora

People at Cencora who can refer or advise you

Requirements
  • Certificate-level qualification in Finance (or equivalent).
  • Relevant bookkeeping/accounting skills and experience.
  • Fluency in English.
  • ERP system experience.
  • Demonstrated experience analyzing variances (Actuals vs Plan; Actuals vs Prior Year).
  • 2–4 years of relevant management experience.
  • 5–7 years of professional experience in a multinational company.
Responsibilities
  • Manage country accounting operations, including AP, AR, GL postings, and banking processes.
  • Ensure timely and accurate preparation of financial statements and required reporting (daily/monthly/quarterly/annual).
  • Lead variance analysis (Actuals vs Plan; Actuals vs Prior Year) and provide clear explanations and actionable insights.
  • Ensure compliance with corporate tax requirements and support filings, documentation, and audits as needed.
  • Maintain and strengthen internal financial controls; ensure adherence to policies and procedures.
  • Coordinate and support internal/external accounting audits; ensure audit readiness and timely issue resolution.
  • Drive continuous improvement by developing, documenting, and optimizing finance processes.
  • Partner cross-functionally with country department heads to support business needs with transparent, professional communication.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

People at Cencora

People at Cencora who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Nucleus scaling expected late 2026 improves real-time tracking, reducing training time and boosting provider adoption efficiency.
  • 2026 OneOncology acquisition strengthens specialty positioning, while AI tools deployed across operations drive digital transformation gains.
  • Cencora raised FY EPS to $17.65–$17.90 despite $2.68B revenue miss, signaling profit resilience and $1B share repurchase plans.

What critics are saying

  • Biosimilar conversions at mail-order pharmacies erode revenue base with 50–70% probability in 6–12 months; impact is high.
  • Inflation Reduction Act price cuts impose $2B quarterly revenue headwind, compressing margins with 60–80% probability in 6–12 months.
  • Q2 $2.68B revenue miss triggered fraud litigation with 35–50% probability of regulatory penalties or class actions in 6–12 months.

What makes Cencora unique

  • Cencora leads in specialty pharmaceutical distribution with Nucleus inventory tech piloted at 20+ sites in Q2 2026.
  • Cencora uniquely integrates CAR T-cell therapy distribution via 2026 Kite agreement, expanding oncology portfolio strategically.
  • Cencora ranks #10 Fortune 500 with $300B+ revenue, offering unmatched scale in pharma distribution and supply chain services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.